Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function

TY - JOUR

T1 - Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function

AU - Liu, Zhengtao

AU - Zhang, Cheng

AU - Lee, Sunjae

AU - Kim, Woonghee

AU - Klevstig, Martina

AU - Harzandi, Azadeh M.

AU - Sikanic, Natasa

AU - Arif, Muhammad

AU - Ståhlman, Marcus

AU - Nielsen, Jens

AU - Uhlen, Mathias

AU - Boren, Jan

AU - Mardinoglu, Adil

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The pathogenesis of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) has been associated with altered expression of liver-specific genes including pyruvate kinase liver and red blood cell (PKLR), patatin-like phospholipase domain containing 3 (PNPLA3) and proprotein convertase subtilisin/kexin type 9 (PCSK9). Here, we inhibited and overexpressed the expression of these three genes in HepG2 cells, generated RNA-seq data before and after perturbation and revealed the altered global biological functions with the modulation of these genes using integrated network (IN) analysis. We found that modulation of these genes effects the total triglycerides levels within the cells and viability of the cells. Next, we generated IN for HepG2 cells, identified reporter transcription factors based on IN and found that the modulation of these genes affects key metabolic pathways associated with lipid metabolism (steroid biosynthesis, PPAR signalling pathway, fatty acid synthesis and oxidation) and cancer development (DNA replication, cell cycle and p53 signalling) involved in the progression of NAFLD and HCC. Finally, we observed that inhibition of PKLR lead to decreased glucose uptake and decreased mitochondrial activity in HepG2 cells. Hence, our systems level analysis indicated that PKLR can be targeted for development efficient treatment strategy for NAFLD and HCC.

AB - The pathogenesis of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) has been associated with altered expression of liver-specific genes including pyruvate kinase liver and red blood cell (PKLR), patatin-like phospholipase domain containing 3 (PNPLA3) and proprotein convertase subtilisin/kexin type 9 (PCSK9). Here, we inhibited and overexpressed the expression of these three genes in HepG2 cells, generated RNA-seq data before and after perturbation and revealed the altered global biological functions with the modulation of these genes using integrated network (IN) analysis. We found that modulation of these genes effects the total triglycerides levels within the cells and viability of the cells. Next, we generated IN for HepG2 cells, identified reporter transcription factors based on IN and found that the modulation of these genes affects key metabolic pathways associated with lipid metabolism (steroid biosynthesis, PPAR signalling pathway, fatty acid synthesis and oxidation) and cancer development (DNA replication, cell cycle and p53 signalling) involved in the progression of NAFLD and HCC. Finally, we observed that inhibition of PKLR lead to decreased glucose uptake and decreased mitochondrial activity in HepG2 cells. Hence, our systems level analysis indicated that PKLR can be targeted for development efficient treatment strategy for NAFLD and HCC.

UR - http://www.scopus.com/inward/record.url?scp=85059704001&partnerID=8YFLogxK

U2 - 10.1016/j.ymben.2019.01.001

DO - 10.1016/j.ymben.2019.01.001

M3 - Article

C2 - 30615941

AN - SCOPUS:85059704001

SN - 1096-7176

VL - 52

SP - 263

EP - 272

JO - METABOLIC ENGINEERING

JF - METABOLIC ENGINEERING

ER -